Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $54,310.92 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 2,686 shares of the stock in a transaction on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $54,310.92. Following the completion of the sale, the insider owned 142,547 shares of the company’s stock, valued at approximately $2,882,300.34. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Up 0.7%

Shares of NASDAQ KALV opened at $19.56 on Thursday. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The stock has a fifty day moving average price of $17.67 and a 200 day moving average price of $15.31. The company has a market cap of $1.00 billion, a P/E ratio of -4.95 and a beta of -0.40. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.83 and a 12-month high of $21.31.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its position in shares of KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of KalVista Pharmaceuticals during the third quarter worth about $55,000. Wolverine Asset Management LLC bought a new position in shares of KalVista Pharmaceuticals during the third quarter worth about $57,000. KLP Kapitalforvaltning AS bought a new position in shares of KalVista Pharmaceuticals during the third quarter worth about $63,000. Finally, Truvestments Capital LLC lifted its position in shares of KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have weighed in on KALV shares. Wall Street Zen cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Stifel Nicolaus upped their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. HC Wainwright upped their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Needham & Company LLC upped their price objective on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, KalVista Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.